DAIC

FEBRUARY 2, 2024

Photo: Edwards Lifesciences milla1cf Fri, 02/02/2024 - 09:33 February 2, 2024 — Edwards Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).

Tricuspid 100

Tricuspid Quality of Life Bicuspid/Mitral Innovation 100

HCPLive

FEBRUARY 2, 2024

The FDA approval of Edwards Lifesciences EVOQUE tricuspid valve replacement system for treatment of symptomatic severe tricuspid regurgitation is the first of its kind for a transcatheter therapy.

Tricuspid 80

Tricuspid 80

Med Page Today

FEBRUARY 12, 2024

(MedPage Today) -- FDA staff questioned the evidence for clinical benefit with the TriClip G4 transcatheter edge-to-edge repair (TEER) system for severe tricuspid regurgitation (TR) in documents released ahead of the agency's Circulatory System.

Tricuspid 97

Tricuspid Document 97

Circulation

APRIL 25, 2024

Tricuspid valve disease is an often underrecognized clinical problem that is associated with significant morbidity and mortality. This review highlights the important background, anatomic considerations, therapeutic options, and future directions with regard to treatment of tricuspid valve disease. Circulation, Ahead of Print.

Tricuspid 80

Tricuspid Pacemaker Heart Failure Pulmonary 80

Frontiers in Cardiovascular Medicine

MARCH 3, 2024

By contrast, the right-sided diseases, particularly the tricuspid valve (TV) and associated regurgitation, still have much to be delineated. Worsening tricuspid regurgitation (TR) is associated with increased mortality; the non-invasive management is suboptimal; and surgical approaches carry significant risk.

Tricuspid 69

Tricuspid Anatomy Heart Disease 69

European Journal of Heart Failure

MARCH 7, 2024

Changes in right ventricular (RV) function and clinical outcomes after tricuspid transcatheter edge-to-edge repair (T-TEER). Among patients with baseline RVFAC <35%, a smaller RV diameter and a greater reduction of tricuspid regurgitation were predictors for the RV responder.

Tricuspid 76

Tricuspid Outcomes Heart Failure Hospital 76

CardiacWire

FEBRUARY 4, 2024

Edwards Lifesciences ended last week with the biggest structural interventions launch that we’ve seen in some time, announcing the FDA approval of its EVOQUE transcatheter tricuspid valve replacement system (TTVR). The post Edwards EVOQUE First FDA-Approved Transcatheter Tricuspid Regurgitation Treatment appeared first on Cardiac Wire.

Tricuspid 59

Tricuspid Quality of Life Medicare 59

American College of Cardiology

DECEMBER 12, 2023

What are the predictors of tricuspid regurgitation (TR) progression and the prognostic impact of TR progression?

Tricuspid 66

Tricuspid Article 66

All About Cardiovascular System and Disorders

MARCH 30, 2024

Transcipt of video: Mild tricuspid regurgitation is often noted on echocadiogram reports and sometimes causes a little bit of worry and a lot of questions are asked on mild tricuspid regurgitation. What is this mild tricuspid regurgitation? And mild tricuspid regurgitation is just a small leak from the tricuspid valve.

Tricuspid 52

Tricuspid Echocardiogram Bicuspid/Mitral Pulmonary 52

Heart BMJ

FEBRUARY 23, 2024

Significant secondary tricuspid regurgitation (STR) has increasing prevalence with age, it is associated with impaired quality of life, and it is an independent predictor of patients’ morbidity and mortality. 3 4 However, the association of RA function with outcomes in patients with STR received less attention.

Tricuspid 74

Tricuspid Quality of Life Outcomes 74

American College of Cardiology

JULY 17, 2024

What is the effect of a transvenous implantable cardioverter-defibrillator (TV-ICD) on tricuspid regurgitation (TR) severity, and secondarily, on right ventricular (RV) size and function?

Tricuspid 66

Tricuspid Defibrillator Article 66

European Journal of Heart Failure

DECEMBER 22, 2023

Abstract Right-sided heart failure and tricuspid regurgitation are common and strongly associated with poor quality of life and an increased risk of heart failure hospitalizations and death.

Heart Failure 75

Heart Failure Tricuspid Cardiovascular Interventions Quality of Life 75

Med Page Today

FEBRUARY 14, 2024

(MedPage Today) -- FDA advisors were nearly unanimous in backing the TriClip G4 transcatheter edge-to-edge repair (TEER) device as a treatment for severe tricuspid regurgitation (TR). During an advisory committee meeting on Tuesday, the FDA's.

Tricuspid 64

Tricuspid 64

DAIC

APRIL 9, 2024

Image courtesy of UC Davis Health milla1cf Tue, 04/09/2024 - 16:47 April 9, 2024 — UC Davis Health cardiology team members are among the first in the country to treat patients with tricuspid regurgitation , or a leaky heart valve, by using a groundbreaking catheter. Tricuspid regurgitation affects an estimated 1.6 million Americans.

Tricuspid 111

Tricuspid Heart Valves Bicuspid/Mitral Quality of Life 111

All About Cardiovascular System and Disorders

MARCH 30, 2024

In Ebstein’s anomaly, there is downward or apical displacement of posterior and septal tricuspid leaflets. The anterior leaflet is not displaced, but is elongated to meet the other leaflets, so that when it closes, a loud sound, tricuspid sound, is produced, which is called as the sail sound.

Tricuspid 52

Tricuspid Arrhythmia Congenital Heart Disease Electrophysiology 52

American College of Cardiology

OCTOBER 27, 2024

Food and Drug Administration (FDA) this year for tricuspid regurgitation (TR) are safe, effective and improve quality of life (QOL) at one year, according to studies published in JACC and simultaneously being presented at TCT 2024. Two devices approved by the U.S.

Quality of Life 60

Quality of Life Tricuspid Article 60

DAIC

JUNE 10, 2024

milla1cf Mon, 06/10/2024 - 17:58 June 10, 2024 — Atrium Health Sanger Heart & Vascular Institute has successfully completed the first commercial tricuspid clip procedure in the Carolinas, performed in May at Atrium Health Carolinas Medical Center. The recent approval of the tricuspid clip device by the U.S.

Heart Valves 109

Heart Valves Tricuspid Open-Heart Surgery Quality of Life 109

American College of Cardiology

DECEMBER 12, 2024

The goal of the TRILUMINATE Pivotal trial was to evaluate percutaneous tricuspid valve transcatheter edge-to-edge repair (TEER) compared with medical therapy among patients with symptomatic severe tricuspid regurgitation.

Tricuspid 49

Tricuspid Outcomes Article 49

American College of Cardiology

MARCH 18, 2024

In this episode, the focus is on tricuspid valve disease. In this panel discussion, host Andrea Price MS, AACC brings together Marcus Burns, DNP, Kristen deAlmeida, PharmD, and Bailey Estes MSN, AGNP-C, to explore best practices related to structural heart disease.

Tricuspid 58

Tricuspid Allied Health Best Practices Nursing 58

American College of Cardiology

APRIL 29, 2024

The following are key points to remember from an American Heart Association scientific statement, which reviews the pathology, imaging, and current treatment options for the tricuspid valve (TV).

Tricuspid 58

Tricuspid Article 58

HCPLive

FEBRUARY 14, 2024

FDA advisory committee votes 13-1 that the benefits outweigh the risk of use for Abbott's TriClip for tricuspid regurgitation, pending FDA decision expected in 2024.

Tricuspid 59

Tricuspid 59

DAIC

JUNE 11, 2024

Columbia University Irving Medical Center’s Division of Cardiology has announced its launch of the Mitral & Tricuspid Center. Tricuspid and mitral valves are debilitating conditions that can lead to arrhythmias, hypertension, and heart failure.

Tricuspid 52

Tricuspid Bicuspid/Mitral Heart Valves Innovation 52

American College of Cardiology

MARCH 25, 2024

The following are key points to remember from a state-of-the-art review about the current status and perspectives on transcatheter treatment of the tricuspid valve (TV).

Tricuspid 53

Tricuspid Article 53

HCPLive

APRIL 26, 2024

A higher TRV was significantly associated with cerebrovascular disease and persistent albuminuria in children with SCD across two large cohorts.

Kidney Disease 98

Kidney Disease Cerebrovascular Disease Tricuspid 98

American College of Cardiology

AUGUST 31, 2024

trial was to assess the efficacy and safety of tricuspid transcatheter edge-to-edge repair (T-TEER) + guideline-directed medical therapy (GDMT) compared with GDMT alone among patients with symptomatic ≥ severe tricuspid regurgitation (TR). The goal of the TRI.Fr

Tricuspid 45

Tricuspid Article 45

Journal of Cardiothoracic Surgery

NOVEMBER 25, 2024

Tricuspid valve replacement (TVR) is required when repair is not feasible, and it continues to be a relatively high-risk procedure owing to the complex medical and/or surgical profile of patients. The choice b.

Tricuspid 52

Tricuspid 52

DAIC

FEBRUARY 21, 2024

Henry Ford Health's Center for Structural Heart Disease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heart failure patient on February 13, 2024 at Henry Ford Hospital in Detroit. million Americans have moderate to severe tricuspid regurgitation. to receive the device.

Heart Failure 105

Heart Failure Open-Heart Surgery Tricuspid Heart Disease 105

Med Page Today

AUGUST 31, 2024

(MedPage Today) -- LONDON -- Tricuspid transcatheter edge-to-edge repair (T-TEER) improved how well patients functioned and felt without major cardiovascular events in the first academic randomized trial to affirm the pivotal trial findings.

Tricuspid 52

Tricuspid Academic 52

Frontiers in Cardiovascular Medicine

JUNE 12, 2024

BackgroundSevere tricuspid regurgitation (TR) causing cyanosis with patent foramen ovale (PFO) and right-to-left atrial shunting requires a precise diagnosis for optimal therapy. Tricuspid valve prolapse (TVP) can lead to TR and is sometimes overlooked, especially in complex cases with factors like pulmonary hypertension (PH).

Tricuspid 52

Tricuspid Pulmonary Echocardiogram Hypertension 52

American College of Cardiology

AUGUST 5, 2024

What are the 1-year clinical outcomes of subjects treated by tricuspid transcatheter edge-to-edge repair (T-TEER) with the TriClip system in a contemporary real-world setting?

Tricuspid 49

Tricuspid Outcomes Article 49

American College of Cardiology

OCTOBER 1, 2024

The tricuspid valve has historically received less attention compared to the valves on the left side of the heart. Tricuspid valve disease, however, is more common than previously thought, and if left untreated, it poses a significant risk of morbidity and mortality.

Tricuspid 45

Tricuspid Article 45

Science Daily - Heart Disease

APRIL 9, 2024

Medical researchers have performed a successful transcatheter tricuspid valve repair procedure with a groundbreaking catheter.

Tricuspid 109

Tricuspid Research 109

Medical Xpress - Cardiology

NOVEMBER 5, 2024

For patients with symptomatic and severe or greater tricuspid regurgitation (TR), transcatheter tricuspid valve replacement (TTVR) plus optimal medical therapy (OMT) yields substantial improvement in symptoms, function, and quality of life, according to a study published online Oct. 27 to 30 in Washington, D.C.

Tricuspid 40

Tricuspid Quality of Life Research 40

Open Heart

JUNE 2, 2022

Severe tricuspid regurgitation (TR) is an undertreated common pathology associated with significant morbidity and mortality. Transcatheter tricuspid valve interventions are a novel and effective therapeutic option for the treatment of significant TR.

Tricuspid 52

Tricuspid 52

ADN Center of Excellence

MARCH 18, 2024

ADN CoE recently hosted a groundbreaking Mitral & Tricuspid Valve Interventions Training, uniting cardiologists from around the globe for an immersive learning experience. Alev Kılıçgedik and Dr. Zeynettin KAYA, attendees gained practical insights and honed their skills in mitral and tricuspid valve interventions.

Tricuspid 52

Tricuspid Bicuspid/Mitral Interventional Cardiology Education 52

Med Page Today

OCTOBER 31, 2024

(MedPage Today) -- The Evoque transcatheter tricuspid valve replacement (TTVR) system continued to show significant benefits 1 year after implant, according to an update from the TRISCEND II trial. Among study participants with symptomatic, severe.

Tricuspid 52

Tricuspid 52

Medical Xpress - Cardiology

NOVEMBER 6, 2024

For patients with symptomatic and severe tricuspid regurgitation (TR), tricuspid transcatheter edge-to-edge repair (T-TEER) yields significant improvements in primary end points, according to a study published online Oct. 27 to 30 in Washington, D.C.

Tricuspid 40

Tricuspid 40